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Myelin membranes are sheet-like extensions of oligodendrocytes that can be considered membrane domains distinct from the
cell’s plasma membrane. Consistent with the polarized nature of oligodendrocytes, we demonstrate that transcytotic transport
of the major myelin-resident protein proteolipid protein (PLP) is a key element in the mechanism of myelin assembly. Upon bio-
synthesis, PLP traffics to myelin membranes via syntaxin 3-mediated docking at the apical-surface-like cell body plasma mem-
brane, which is followed by subsequent internalization and transport to the basolateral-surface-like myelin sheet. Pulse-chase
experiments, in conjunction with surface biotinylation and organelle fractionation, reveal that following biosynthesis, PLP is
transported to the cell body surface in Triton X-100 (TX-100)-resistant microdomains. At the plasma membrane, PLP tran-
siently resides within these microdomains and its lateral dissipation is followed by segregation into 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate (CHAPS)-resistant domains, internalization, and subsequent transport toward the my-
elin membrane. Sulfatide triggers PLP’s reallocation from TX-100- into CHAPS-resistant membrane domains, while inhibition
of sulfatide biosynthesis inhibits transcytotic PLP transport. Taking these findings together, we propose a model in which PLP
transport to the myelin membrane proceeds via a transcytotic mechanism mediated by sulfatide and characterized by a confor-
mational alteration and dynamic, i.e., transient, partitioning of PLP into distinct membrane microdomains involved in biosyn-
thetic and transcytotic transport.
Oligodendrocytes (OLGs) synthesize a multilamellar mem-brane structure known as the myelin sheath (in vitro: myelin
sheet), which extends from their plasma membrane and wraps
around axons, thereby facilitating rapid saltatory conduction and
axonal survival in the central nervous system. Myelin is enriched
in galactolipids and cholesterol and contains myelin-specific pro-
teins, themajor ones of which aremyelin basic protein (MBP) and
proteolipid protein (PLP) (1–3). In generating a myelin mem-
brane, OLGs acquire a polarized phenotype. The sphingolipid-
enriched myelin membrane is served by a basolateral-surface-like
mechanism, while the cell body plasmamembrane is served by an
apical-surface-like transportmechanism (4–8).MBP andPLP sta-
bilize apposedmyelinmembrane surfaces in compactmyelin, and
their transport routes are segregated. Thus, following its biosyn-
thesis at the rough endoplasmic reticulumandprocessing through
the Golgi apparatus (9, 10), the transmembrane protein PLP is
transported via vesicles to the myelin membrane (11, 12). In
marked contrast, MBP, a peripheral membrane protein facing the
cytoplasm, is synthesized at and associates with the myelin mem-
brane on site, involving myelin membrane-directed transport of
its mRNA rather than the native protein (13, 14). In addition, to
limit ectopic assembly and premature compaction of myelin
membranes, the protein-mediated biogenesis of myelin mem-
branes is tightly regulated in both time and space (reviewed in
reference 6). In fact, MBP associates with myelin membranes
prior to PLP (2). Regulation of the trafficking of either protein is
under tight neuronal control, with MBP trafficking being regu-
lated mainly by adhesive interactions (15, 16) while the flow of
PLP appears to be governed by secreted factors (17). Clearly, de-
fining the processes of cellular sorting and transport is essential for
an understanding of both normal OLG development and the pro-
cess of remyelination in demyelinating diseases such as multiple
sclerosis (MS), in which myelin membrane organization is per-
turbed. For example, the molecular composition of the myelin
galactolipid sulfatide and MBP in MS differs from their composi-
tion under control conditions (18, 19), while paranodal structures
are disrupted (20, 21).
The underlying sorting machinery by which PLP reaches its
final destination is still unclear, but insight into the overall trans-
port pathway is gradually emerging and favors indirect transport
of PLP to myelin. Thus, prior to reaching the myelin membrane,
PLP is sorted to and stored in a late LAMP1-positive endosomal
compartment (11, 17, 22), from where the protein, along with
cholesterol and in galactosylceramide (GalC)-enriched microdo-
mains, is subsequently transported to the myelin membrane (17).
To reach this late endosomal compartment, PLP is internalized
from the plasma membrane via clathrin-independent but choles-
terol-dependent endocytosis (17, 22, 23). Recently, delivery of
PLP to the surface has been claimed to occur by two independent
pathways, involving the vesicle-soluble N-ethylmaleimide-sensi-
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tive factor attachment protein receptors (v-SNAREs) VAMP3 and
VAMP7, respectively (24). Therefore, in line with the presence of
polarity-based transport mechanisms in OLGs, newly synthesized
PLPmight reach its final destination via an indirect pathway. Con-
sistent with this hypothesis is the observation that PLP, stably
expressed in polarized Madin-Darby canine kidney cells, is
transported to the apical rather than the basolateral surface
(25), i.e., membrane domains reminiscent of the cell body
plasma membrane and the myelin sheet in cultured OLGs, re-
spectively (4, 5).
Thus far, knowledge concerning the docking of PLP and its
final insertion into the myelin membrane is scanty. A variety of
syntaxins, i.e., membrane-localized target SNAREs (t-SNAREs)
involved in the docking and fusion of transport vesicles at target
membranes, have been detected in OLGs (6, 26, 27), including
syntaxins 3 and 4, the respective putative binding partners of
VAMP7 and VAMP3 (24, 27). Specifically, in previous work, we
have shown a polarized distribution of these syntaxins, with syn-
taxin 3 localizing largely at the plasma membrane of the OLG cell
body whereas syntaxin 4 is enriched at the myelin sheet (6). To
obtain further insight into the molecular mechanism underlying
PLP trafficking and its assembly intomyelinmembranes, the pres-
ent study was undertaken. Our data demonstrate that PLP is
transported to themyelinmembrane via a transcytotic route, with
first localization at theOLG cell body plasmamembrane involving
syntaxin 3 and then a sulfatide-facilitated shift into a different
lateral plasmamembrane pool, accompanied by a conformational
alteration and/or oligomerization, prior to the protein’s delivery
to the myelin sheet.
MATERIALS AND METHODS
Cell cultures. (i) OLGs. Primary cultures of OLGs were prepared from
forebrains of 1- to 2-day-old Wistar rats as described previously (28, 29).
OLG progenitor cells (OPCs) were plated in SATOmedium (28) supple-
mented with the growth factors fibroblast growth factor 2 (FGF-2) (10
ng/ml; Peprotech, London, United Kingdom) and platelet-derived
growth factor-AA (10 ng/ml; Peprotech) on poly-L-lysine (PLL, 5 g/ml;
Sigma, St. Louis, MO)-coated 10-cm dishes (Nunc, Naperville, IL) at
1.0  106 cells/dish or eight-well Permanox chamber slides (Nunc) at
20,000 cells/well for biochemical and immunocytochemical analyses, re-
spectively. After 2 days, differentiationwas initiated by switching to SATO
supplemented with 0.5% fetal calf serum (FCS; Bodinco, Alkmaar, The
Netherlands) and cells were grown for 3 days (immature OLGs
[imOLGs]) or 7 to 10 days (mature OLGs [mOLGs]). To inhibit sulfatide
biosynthesis, cells were cultured in the presence of 30Msodiumchlorate
for at least 4 to 7 days. All experimental procedures were approved by the
Animal Ethical Committee of the University Medical Center Groningen
(UMCG).
(ii) OLN-PLP cells. OLN-PLP cells were made in the laboratory of
Zeger Debyser (University of Leuven, Leuven, Belgium) in collaboration
with Rik Gijsbers and Veerle Baekelandt (University of Leuven, Leuven,
Belgium) and were a kind gift of Ellen Gielen (Hasselt University, Hasselt,
Belgium). Briefly, PLP was cloned into the lentiviral plasmid pCOMBI-
eGFP-IRES-puro and PLP-enhanced green fluorescent protein (eGFP)-
containing lentiviral particles were produced by using HEK-293T cells.
Subsequently, the rat-derived oligodendroglia-derived cell lineOLN-93, a
kind gift of Christiane Richter Landsberg (University of Oldenburg, Old-
enburg, Germany) (30) was lentivirally transduced with PLP-eGFP-con-
taining lentiviral particles. OLN-PLP cells were cultured in Dulbecco’s
modified Eagle’smedium (DMEM) containing 10%heat-inactivated FCS
and 2 g/ml puromycin (Sigma). Cells were plated on eight-well Per-
manox chamber slides for immunocytochemistry analysis (5,000 cells/
well) or on 10-cm tissue culture dishes for biochemical analysis (500,000
cells/well). Cells were grown inDMEM supplementedwith 10%FCS for 3
days, unless otherwise indicated.
(iii) HepG2 cells. HepG2 cells were cultured in DMEM containing
10% FCS. Transfection of HepG2 cells with plasmid pLEGFP-N1-PLP
was performed with Lipofectamine 2000 (Invitrogen, Breda, The Nether-
lands) according to the manufacturer’s instructions. After transfection,
the cells were cultured in the presence of 1.0 mg/ml Geneticin (G418;
Invitrogen) and colonies were isolated 14 days after transfection. Stably
transfected cells were plated on eight-well Permanox chamber slides for
immunocytochemistry analysis (5,000 cells/well) or on 10-cm tissue cul-
ture dishes for biochemical analysis (500,000 cells/well).
Constructs. The cDNAs encoding syntaxins 3 and 4were a kind gift of
Thomas Weimbs (University of California, Santa Barbara, CA) (31), and
PLP-eGFP was a kind gift of Niels Hellings (Hasselt University, Hasselt,
Belgium). For cloning of the syntaxin 3 and 4 genes into retroviral vector
pLXIN (Clontech Biosciences, Mountain View, CA), an XhoI restriction
site at the ATG start codon and an XhoI restriction site after the stop
codon were introduced by PCR. The primers used were 5=-CATGTATT
CGAAGAGCTCTTCGCACATG-3= (forward syntaxin 3), 5=-CTAGGTG
ATCAAGAGCTCCTAGGGCCCACG-3= (reverse syntaxin 3), 5=-CGAA
TAGCTATGAGCTCCATGGTCTAG-3= (forward syntaxin 4), and 5=-G
ATCTCCTAGAGCTCACGTAGGGAC-3= (reverse syntaxin 4). The
cDNAs encoding ceramide sulfatide transferase (CST) and ceramide
galactosyltransferase (CGT) were kind gifts of Matthias Eckhardt (Uni-
versity of Bonn, Bonn, Germany) and Brian Popko (University of Chi-
cago, Chicago, IL), respectively. For cloning, the genes for CST and CGT
were inserted into the EcoRI site of the retroviral vector pLXIN (Clontech
Biosciences, Mountain View, CA). The orientation and integrity of the
pLXIN constructs obtained were confirmed by DNA sequencing.
Retroviral transduction. The production of retroviral particles and
the subsequent infection of OPCs and OLN-PLP cells were performed
according to Klunder et al. (5) and Maier et al. (32), respectively, Trans-
ductions were carried out by exposing cells to retroviral particles and 8
g/ml hexadimethrine bromide (Polybrene; Sigma) for 16 to 18 h. The
cells were cultured for 24 h and then cultured with selection under pro-
liferating conditions in the presence of 400 g/ml (OPCs) or 2 mg/ml
(OLN-PLP cells) G418 (Roche, Mannheim, Germany) for 5 days. OLN-
PLP cells were first infected with CGT (OLN-PLP-G cells) and then se-
lected; this was followed by a second infection with CST (OLN-PLP-GS
cells). An OLN-mock cell line was obtained by retroviral infection with
the vector only (pLXIN). The transduction efficiency was nearly 100%.
OLN-PLP-G and OLN-PLP-GS cells were cultured in the presence of 2
g/ml puromycin and 2 mg/ml G418.
PLP antibodies. PLP consists of four hydrophobic -helices that span
the lipid bilayer with two extracytoplasmic domains and three cytoplas-
mic domains, while both the C and N termini face the cytoplasm (33, 34).
Anti-PLP antibodies 4C2, directed against a nonconformational epitope
in the first extracellular loop (PLP amino acids 50 to 69), and 2D2, di-
rected against an intracellular region absent from DM-20 (PLP amino
acids 100 to 123), were kind gifts of Vijay Kuchroo (Harvard Medical
School, Boston, MA) (35). The epitope recognized by anti-PLP antibody
O10 is acquired posttranslationally and is directed against a conforma-
tion-dependent epitope in the second extracellular loop (kind gift of Evi
Albers-Krämer, Mainz, Germany) (36). The anti-PLP antibody ET3 was
raised in rabbits against the second extracellular loop of PLP. To this end,
a synthetic peptide, PLP181-230, with the two disulfide bridges was gen-
erated (37). Two rabbits were injected subcutaneously on days 0, 21, and
35 with an emulsion containing 300 g of this synthetic peptide in
Freund’s complete (day 0) or incomplete (days 21 and 35) adjuvant. At
day 49, 600 g of the peptide in incomplete adjuvant was injected. The
rabbits were bled on day 56, and the serumwas kept frozen at20°C. The
ET3 antibody reacts with the peptide in an enzyme-linked immunosor-
bent assay and recognizes a conformational epitope, given the absence of
a band in reducing Western blot assays (data not shown).
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Pulse-chase experiments. ImOLGs were preincubated in DMEM
without methionine (Invitrogen, Breda, The Netherlands) for 1 h and
then labeled for 10 min with Tran35S-label (GE Healthcare, Biosciences,
Buckinghamshire, United Kingdom) at 200Ci/dish. The cells were then
chased with medium supplemented with 10 mM methionine (Merck,
Darmstadt, Germany) for 0, 15, 30, and 60 min. Cells were scraped into
phosphate-buffered saline (PBS), extracted with TNE lysis buffer (20mM
Tris-HCl [pH 7.4], 150 mM NaCl, and 1 mM EDTA supplemented with
1% Triton X-100 [TX-100] and a cocktail of protease inhibitors [Com-
pleteMini; Roche]) for 30min at 4°C, and separated by centrifugation (15
min at 13,300 g) into TX-100-soluble supernatants and TX-100-insol-
uble pellets. PLP was immunoprecipitated from both fractions with pro-
tein G-Sepharose (GE Healthcare) beads overnight at 4°C. Protein G-
Sepharose beads were washed four times with TNE lysis buffer
supplemented with 0.2% SDS and once with PBS. Washed protein G-
Sepharose beads were resuspended in SDS sample buffer and counted for
2 min in a microplate scintillation and luminescence counter (Packard
Instrument Company, Meriden, CT).
Preparation of detergent extracts. Cells were washed with PBS and
harvested by scraping the cells in TNE lysis buffer containing either 1%
TX-100 or 20 mM 3-[(3-cholamidopropyl)-dimethylammonio]-1-pro-
panesulfonate (CHAPS). The solution was passed 10 times through a
21-gauge needle and incubated on ice for at least 30 min. The protein
content was determined by a DC protein assay (Bio-Rad Laboratories,
Hercules, CA) using bovine serum albumin (BSA) as a standard.
OptiPrep density gradient centrifugation. For density gradient cen-
trifugation, a discontinuousOptiPrep gradient was prepared. To this end,
250 l of total cell detergent extracts (equal protein) was added to 500 l
of 60%OptiPrep. This 40%OptiPrep solution was overlaid with 30% and
10%OptiPrep. Gradients were centrifuged overnight at 152,000 g (4°C,
Beckman SW55 rotor), and seven gradient fractions were collected from
the top (fraction 1) to the bottom (fraction 7). To concentrate proteins,
equal fraction volumes were adjusted to a final volume of 1 ml with TNE
buffer and treated with deoxycholate (125 g/ml) for 5 min at 4°C; this
was followed by precipitation with 6.5% trichloric acid (TCA) for 15 min
at 4°C. Precipitates were centrifuged for 20min at 9,200 g and 4°C. The
pellets were dried and resuspended in SDS reducing sample buffer. After
the pH was adjusted to 6.8 by exposure to ammonia, the samples were
heated for 30 min at 37°C and subjected to SDS-PAGE andWestern blot-
ting. The lateral distribution of PLP-eGFP was calculated from the pro-
tein’s (infrared) intensity in either fractions 3 and 4 (membranemicrodo-
mains) or fractions 6 and 7 (nonmembrane microdomains), relative to
the total intensity, i.e., measured collectively in all of the fractions.
Surface biotinylation. Cells were washed twice with ice-cold PBS and
incubated for 1 h with sulfo-NHS-L-C-biotin (0.1 mg/ml in PBS; Pierce,
Rockford, IL) at 4°C. The cells were washed three times for 5 min each
with cell wash buffer (CWB; 65 mM Tris-HCl [pH 7.5], 150 mMNaCl, 1
mM CaCl2, 1 mM MgCl2) to remove excess biotin and twice with PBS.
The cells were harvested by being scraped into 350 l of TNE lysis buffer
and pressed 18 times through a 21-gauge needle. Lysis occurred on ice for
30 min, and the protein content was determined by the Bio-Rad DC
protein assay. Equal amounts of protein were centrifuged for 20 min at
15,600  g to obtain soluble and insoluble fractions or subjected to Op-
tiPrep density gradient centrifugation. Biotinylated proteins were immu-
noprecipitated from equal volumes of the fractions with streptavidin
(SA)-agarose for 16 to 18 h at 4°C. After centrifugation, the SA-agarose
beads (biotinylated proteins) were washed four times with CWB supple-
mented with 1% NP-40 and 0.35 M NaCl and once with PBS. Nonbioti-
nylated proteins (supernatants) were concentrated by TCA precipitation
as described above. Samples from SA-agarose beads (surface) and super-
natant (intracellular) fractions were mixed with SDS reducing sample
buffer, heated for 2 min at 95°C or 30 min at 37°C, and subjected to
SDS-PAGE and Western blotting.
Isolation of endosomes and lysosomes. Endosome- and lysosome-
enriched fractions were isolated from cells by the flotation gradient frac-
tionation method (38, 39). Cells were harvested by being scraped into a
mixture of 250mM sucrose, 20mMHEPES, and 0.5mMEGTA at pH 7.0
(homogenization buffer [HB]) and immediately subjected to the isolation
procedure. Cells were washed twice with HB by centrifugation at 800 g
for 5 min at 4°C. The pellet was resuspended in 1 ml of HB supplemented
with protease inhibitors and homogenized with a grinding glass cell
Dounce homogenizer (15 loose and 10 tight). The homogenate was
centrifuged at 800  g for 10 min at 4°C. The postnuclear supernatant
obtained was centrifuged at 15,000  g for 15 min at 4°C to remove
mitochondria. Subsequent centrifugation of the supernatant at 128,000 g
for 1 h at 4°C removed the microsomal fraction. The remaining endo-
some- and lysosome-enriched fractions were separated from each other
on a discontinuous sucrose density gradient. To this end, the pellet was
resuspended in 1 ml of a 40.6% sucrose solution and passed 10 times
through a 25-gauge needle. The 40.6% sucrose–proteinmixture was over-
laid sequentially with sucrose solutions of 35% (1.5 ml), 30% (1.5 ml),
25% (2 ml), and HB (6 ml). The gradient was centrifuged at 125,000 g
for 2 h at 4°C (SW41-Ti rotor). Fractions of 1 ml were collected from the
top (fraction 1) to the bottom (fraction 12). The fractions were diluted
with 2 ml of 20 mMHEPES and 0.5 mM EGTA at pH 7.0 and centrifuged
at 153,000  g for 30 min at 4°C (TLA 100.3 rotor). Pellets were resus-
pended in 160l of TNE, passed five times through a 25-gauge needle, and
stored at20°C. Of note, the pellets of fractions 1 to 4 were pooled.
Analysis of cellular glycosphingolipids. Cells were washed three
times with PBS, harvested by scraping in PBS, and centrifuged at 9,200
g at room temperature (RT); this was followed by lipid extraction of the
cell pellet according to Bligh and Dyer (40). Lipids were separated
on thin-layer chromatography (TLC) plates by using C3H6O2-
CH3CH(OH)CH3-CHCl3-CH3OH–25%KCl (25:25:25:10:9, vol/vol/vol/
vol/vol) as the running solvent. To visualize the glycosphingolipids, the
plates were dried and sprayed with 10% H2SO4 and 5% CH3OH and
heated to 120°C.
Immunocytochemistry analysis and in situ extraction. Antibody
staining of cell surface components was performed on living cells at 4°C.
After blocking of nonspecific binding with 4% BSA in PBS, cells were
incubated with anti-surface PLP antibodies 4C2 (1:5), ET3 (1:50), and
O10 (1:3) orwith antisulfatide antibodyO4or anti-GalC antibodyO1 (1:1
and 1:10, respectively; kind gifts of Guus Wolswijk) (41) for 30 min;
washed three times; and incubated for 25 min with appropriate fluores-
cein isothiocyanate (FITC)- or tetramethyl rhodamine isocyanate
(TRITC)-conjugated secondary antibodies (Jackson ImmunoResearch,
West Grove, PA). The cells were fixed with 4% paraformaldehyde (PFA;
Merck) in PBS for 20 min at RT. For double or single staining of intracel-
lular antigens, PFA-fixed cells were permeabilized and blocked with 0.1%
TX-100 and 4% BSA, respectively, in PBS for 30min at RT. The cells were
incubated for 1 to 2 hwith anti-PLP (1:5, 4C2 or 2D2), anti-MRP2 (1:300,
Axxora, Lörrach, Germany), or anti-GFP antibodies (1:100; Invitrogen,
Molecular Probes, Eugene, OR) at RT. The cells were washed with PBS
and incubated with appropriate FITC- or TRITC-conjugated secondary
antibodies and 4=,6-diamidino-2-phenylindole (DAPI, 1 g/ml; Sigma)
for 25min at RT. After beingwashedwith PBS, the cells were coveredwith
2.5% 1,4-diazobicyclo[2.2.2]octane (DABCO) in 90% glycerol–10% PBS
to prevent image fading. For in situ extraction, cells were exposed to cold
0.5%TX-100 or 10mMCHAPS in PBS for 2min at 4°C; this was followed
by PFA fixation at 4°C. The samples were analyzed with a conventional
immunofluorescence microscope (Olympus AX70) equipped with analy-
SIS software or by confocal microscopy with a TCS SP2 or SP8 AOBS
confocal laser scanner microscope (Leica Heidelberg, Germany) in com-
bination with Leica Confocal software. Data were processed using Adobe
Photoshop software.
Dot blotting.Equal volumes (10l) of gradient fractionswere applied
to nitrocellulose membranes. When dried, the membranes were incu-
bated for 1 h at RT in blocking solution (5% nonfat dry milk in PBS); this
was followed by overnight incubation with the antisulfatide O4 antibody
(ammonium sulfated precipitated, O4 at 1:750). After washing with PBS
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containing 0.1% Tween 20 (PBS-T), the membranes were incubated for 2
h with horseradish peroxidase-conjugated anti-IgM antibodies in 1%
nonfat dry milk in PBS-T. Signals were detected by enhanced chemilumi-
nescence (GE Healthcare).
Antibody trafficking assay. The basolateral surface of HepG2 cells
that were stably transfected with PLP-eGFP was labeled with primary
antibodies diluted in 0.2%BSA in PBS for 30min on ice; this was followed
by a 90-min chase in culture medium at 37°C. The primary antibodies
used were anti-extracellular PLP ET3 (1:5) and anti-dipeptidylpeptidase
IV (DPPIV; R&D Systems) antibodies. The tight junctions prevent access
of the antibodies to apical membrane (42). Cells were fixed in 4% PFA for
30 min on ice, permeabilized with ice-cold methanol for 10 min, blocked
with 4% BSA in PBS, and incubated with the appropriate TRITC-labeled
secondary antibodies. Transcytosis of the antibody-antigen complex to
the apical surface was analyzed with a conventional immunofluorescence
microscope (Olympus AX70) equipped with analySIS software.
SDS-PAGE and Western blotting.Equal volumes (gradient fractions)
or protein amounts (cell lysates) were mixed with SDS reducing sample
buffer, heated for 5 min at 95°C (syntaxin 3, syntaxin 4, GFP, caveolin,
LAMP1, EEA1) or 30min at 37°C (PLP) and subjected to SDS-PAGE and
Western blotting. Samples were loaded onto 10 or 12.5% SDS-polyacryl-
amide gels, transferred to Immobilon-FL (Millipore, Bedford, MA) by
semidry blotting, and subjected to immunoblot detection as described
previously (29). The primary antibodies used were anti-syntaxin 3 (1:
1,000; Synaptic Systems, Göttingen, Germany), anti-syntaxin 4 (1:500;
Synaptic Systems), anti-PLP (1:100; 4C2 or 2D2), anti-GFP (1:500), anti-
caveolin-1 (BD Transduction Laboratories, Lexington, KY), anti-LAMP1
(1:250; GeneTex Inc., Irvine, CA), and anti-EEA1 (1:250; Abcam, Cam-
bridge, United Kingdom) antibodies. The signals were detected with the
Odyssey infrared imaging system (Li-Cor Biosciences, Lincoln, NE) and
analyzed with Odyssey V3.0 analysis software.
Statistics. Data are expressed as the mean values of at least three inde-
pendent experiments the standard deviations (SDs). Statistical analysis
was performed with the Student t test when two means were compared
and with a one-sample t test when a value was compared to the control,
which was set to 100% in each independent experiment. When absolute
values ofmore than twomeanswere compared, statistical significancewas
calculated by one-way analysis of variance (ANOVA), followedbyTukey’s
posttest. In all cases, P 0.05 was considered significant.
RESULTS
PLP undergoes a conformational alteration during transport to
the myelin membrane. The multimembrane-spanning protein
PLP is integrated into the myelin membrane via vesicular trans-
port. To accurately define its intracellular trafficking pathway fol-
lowing biosynthesis in primary OLGs, we first determined the
localization of PLP at the onset of myelination (imOLGs) and at a
more advanced stage (mOLGs). In imOLGs, when processes de-
velop, PLP is abundantly localized in vesicular structures in the
perinuclear region of the cell (Fig. 1A), often showing a punctate
appearance when associated with primary processes. Further-
more, in a subset of cells, prominent labeling of the plasma mem-
brane was observed (Fig. 1A, arrow), suggesting an association of
PLP with the plasma membrane of the cell body. Next to its pres-
ence in the cell body, in mature, well-differentiated OLGs, PLP
localizes in particular to vesicular structures in the processes and
myelin sheets (Fig. 1A). Staining of live cells with anti-PLP anti-
body ET3 (directed against a synthetic second extracellular loop)
(37) and O10 (directed against a conformational epitope) (36)
confirmed the presence of PLP at the cell body plasmamembrane
andmyelin sheet (Fig. 1B). Remarkably, although both antibodies
are directed against a conformational epitope in the second extra-
cellular loop, ET3 most prominently binds to PLP present at the
cell body plasmamembrane, whereasO10 staining ismore intense
when PLP is localized in the processes and myelin sheets. This
staining pattern was unaltered upon double labeling, implying
that the antibodies detect different epitopes in the protein when
present at either the cell body plasma membrane or the myelin
membrane (Fig. 1C). Since the secondary structure of the extra-
cellular loop changes as a function of the environment (37), the
data might thus indicate that PLP undergoes conformational al-
terations during transport and/or oligomerizes in a molecular-
environment-dependent manner.
Overexpression of syntaxin 3 inhibits cell body plasma mem-
brane-directed transport of PLP. In previous work, we have
FIG 1 PLP undergoes a conformational alteration during transport to myelin membranes. (A) Localization of PLP in developing OLGs analyzed by immuno-
staining (4C2). Note that in imOLGs, PLP is localized at the cell body plasmamembrane (arrows), whereas inmOLGs, PLP-containing vesicular structures in the
perinuclear region and myelin sheet were observed. (B, C) Surface staining of mOLGs with anti-PLP antibodies that recognize an extracellular epitope (ET3,
O10). Single labeling is shown in panel B, and double labeling is shown in panel C.Note that ET3 binds primarily to the cell body plasmamembrane, whereasO10
staining is more prominent in the myelin sheet. Representative pictures of four independent experiments are shown. The scale bars are 10 m.
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shown that the t-SNARE syntaxin 3, which localizes predomi-
nantly at the apical plasma membrane in epithelial cells (43, 44),
largely localizes at or near the plasma membrane of the OLG cell
body (6), which is served by an apical-surface-like vesicular trans-
port route (4, 5). In contrast, syntaxin 4, which localizes in the
basolateral domain of epithelial cells (43, 44), localizes at the my-
elin membrane in cultured OLGs (6). To assess whether PLP
transport toward the myelin sheet relies on transcytosis, i.e., in-
volves prior transport to and delivery at the cell body plasma
membrane,we examined the effect of syntaxin 3 and 4 overexpres-
sion on PLP localization. Overexpression of syntaxins leads to
nonfunctional SNARE complexes (43), thus mimicking a domi-
nant negative approach.Double labelingwith anti-PLP antibodies
recognizing extracellular (O10) and intracellular (2D2) PLP
epitopes (35, 36) revealed that in OLGs that overexpress syntaxin
3, transport of PLP tomyelin sheets was apparently blocked, while
in cells that overexpress syntaxin 4, PLP is present at the surface
(Fig. 2A). Thus, at approximately 5-fold overexpression of syn-
taxin 3, PLP prominently accumulated in intracellular vesicles in
the cell body, with no significant appearance at the cell body
plasmamembrane or in themyelin sheet (Fig. 2A,middle panels).
Importantly, upon syntaxin 3 and 4 overexpression, no difference
from mock (vector-only)-transduced cells in the number of cells
expressing PLP was observed (data not shown). Hence, our data
suggest that malfunctioning of plasma membrane-localized syn-
taxin 3, as a consequence of its overexpression, precludes docking
of PLP-containing transport vesicles, which remain trapped in the
cell body cytoplasm.
Following biosynthesis, PLP transiently associates with TX-
100-resistant microdomains. To obtain further support and
mechanistic insight into the potential involvement of a transcy-
totic mechanism underlying myelin-directed trafficking of PLP,
we next examined PLP dynamics by characterizing its lateral
membrane organization with detergent insolubility as a criterion.
FIG 2 Overexpression of syntaxin 3 inhibits surface transport of PLP inOLGs concomitant with TX-100 resistance. (A, B)OPCswere transducedwith the vector
only (mock), syntaxin 3 (S31), or syntaxin 4 (S41). (A) Surface and intracellular localization of PLP in mOLGs as determined by immunostaining with
anti-PLP antibodies directed against extracellular (O10) and intracellular PLP epitopes (2D2). Syntaxin 3 and 4 overexpression was confirmed by Western
blotting. Note the lack of PLP surface expression upon the overexpression of syntaxin 3. (B) TX-100 and CHAPSmembranemicrodomain association of PLP in
mOLGs. PLP (4C2) and caveolin were visualized by Western blotting. Detergent-resistant membrane microdomains are present in fractions 3 and 4. Note that
PLP is TX-100 resistant in syntaxin 3-overexpressing OLGs but largely TX-100 soluble in mock-transduced OLGs. (C) ImOLGs were pulse-labeled with
Tran35S-label and chased for the times indicated. PLP was immunoprecipitated from the TX-100-soluble (black bars) and -insoluble (white bars) fractions, and
the amounts were analyzed by radioactivity counting. The statistical significance of differences between 0-min values and values obtained at the time points
indicated is shown (n 3; **, P 0.01; ***, P 0.001; one-way ANOVA with Tukey’s posttest). Note that following biosynthesis, PLP is transiently TX-100
resistant. (D) Cell surface proteins of mOLGs were biotinylated, lysed, and subjected to TX-100 extraction and OptiPrep density gradient centrifugation.
Biotinylated, surface-localized proteins and nonbiotinylated, i.e., intracellularly localized, proteins were separated by SA immunoprecipitation. PLP was visu-
alized by Western blotting (4C2 antibody). Note that TX-100-resistant PLP is present at the surface. (E) imOLGs were subjected to in situ detergent extraction
with either TX-100 or CHAPS prior to fixation. Note that TX-100-resistant PLP localized to the cell body plasmamembrane (arrow), whereas CHAPS-resistant
PLP resided mainly intracellularly. Pictures and blots representative of at least three independent experiments are shown. The scale bars are 10 m.
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It has been well documented that PLP ultimately integrates into
CHAPS-resistant membrane microdomains (11, 45). Given the
apical-surface-like nature of trafficking directed toward the cell
body plasmamembrane inOLGs (4, 5), the observed inhibition of
PLP transport to the surface upon overexpression of syntaxin 3
therefore suggests inhibition of an apical-surface-directed PLP
transport step. In general, apical protein transport is associated
with the protein’s integration into TX-100-resistant membrane
microdomains (4, 46). To verify this in the case of PLP transport,
syntaxin 3-overexpressingOPCswere allowed to differentiate into
myelin sheet-forming mOLGs, extracted with either CHAPS or
TX-100, loaded onto an OptiPrep density gradient, and analyzed
byWestern blotting.Whereas PLP essentially localized toTX-100-
soluble (Fig. 2B, fractions 6 and 7, approximately 60%) but
CHAPS-insoluble fractions (Fig. 2B, fractions 3 and 4, approxi-
mately 75%) inmock-transduced cells, in syntaxin 3-overexpress-
ing cells, PLP was largely recovered in the TX-100-insoluble frac-
tion (Fig. 2B, fractions 3 and 4, approximately 39%) andmuch less
so in the CHAPS-insoluble fraction (Fig. 2B, fractions 3 and 4,
approximately 46%). Caveolin, a control protein present inmem-
brane microdomains, remained insoluble under the conditions
used (Fig. 2B), indicating that, rather than a general phenomenon,
the effect of syntaxin 3 on lateral distribution is specific for PLP
transport. Thus, these data suggest that PLP, following its biosyn-
thesis, transiently integrates intoTX-100-resistantmicrodomains,
reflecting the apical-surface-like plasma membrane-directed
transport mechanism. To verify this potential scenario further, a
pulse-chase experiment was carried out to better define the initial
steps in PLP trafficking. OLGs were metabolically labeled with
Tran35S-label for 10 min at 37°C. Subsequently, excess nonradio-
active methionine was added and the cells were chased for 0, 15,
30, and 60 min, followed by extraction with TX-100 and analysis
of radiolabeled PLP in the pellet (insoluble) and supernatant (sol-
uble). As shown in Fig. 2C, during the first 15 min following de
novo biosynthesis of PLP, essentially the entire PLP fraction was
presentwithin aTX-100-resistant fraction (white bars), while over
the next 45 min, PLP gradually partitioned into a TX-100-soluble
fraction (black bars). To determine whether TX-100-resistant
PLP-containingmembrane fractions are, in fact, present at the cell
surface, mOLGs were surface biotinylated, followed by TX-100
extraction and OptiPrep density gradient fractionation. To sep-
arate surface-localized (i.e., biotinylated) TX-100-resistant PLP
from intracellular (i.e., nonbiotinylated) TX-100-resistant PLP,
the gradient fractions were subjected to SA precipitation and an-
alyzed byWestern blotting. As shown in Fig. 2D, PLP was present
at the surface and this surface pool partitioned roughly equally
between the TX-100-resistant (fractions 3 and 4, approximately
39%) and TX-100-soluble fractions (fractions 6 and 7, approxi-
mately 42%). Of the intracellular fraction, less than 15% was re-
sistant to solubilization by TX-100. As this biochemical character-
ization does not provide information about the actual (surface)
membrane localization of PLP, i.e., cell body plasma membrane
versus myelin sheet, we next visualized PLP in TX-100-resistant
membrane domains by in situ extraction with TX-100 prior to
fixation. TX-100-resistant PLP was observed mainly in the cell
body plasma membrane (Fig. 2E, arrow). In contrast, CHAPS-
resistant PLP resides mainly intracellularly. Hence, these findings
are consistent with the notion that de novo-synthesized PLP is
initially assembled into TX-100-insoluble membrane microdo-
mains localized within transport vesicles that presumably dock by
a syntaxin 3-dependent mechanism at the plasma membrane.
During this early processing, the protein appears to reside tran-
siently inmembranemicrodomains at the cell body plasmamem-
brane that are TX-100 resistant. The prominent intracellular
CHAPS resistance of PLP then presumably reflects the ensuing
transport vesicle-mediated processing of the protein from the
plasma membrane toward the myelin sheet. To obtain further
support for the ability of PLP to engage in a transcytotic transport
route, PLP transport was analyzed in the well-polarized hepatic
cell line HepG2.
PLP is present in apical and basolateral domains of polarized
HepG2 cells. Polarized HepG2 cells display two structurally and
functionally different plasma membrane domains (Fig. 3A). The
two membrane domains are separated by tight junctions and
comprise the apical membrane, which faces the bile canaliculus
(BC), and the basolateral domain, which faces adjacent cells. In
these cells, direct routes for basolateral and apical delivery exist, as
well as indirect transcytotic routes (47). More specifically, our
previous work showed that in these cells, resident apical proteins
may employ different pathways to reach the apical surface follow-
ing biosynthesis (42). Thus, whereas single transmembrane pro-
teins traffic to the apicalmembrane via the basolateralmembrane,
multimembrane-spanning proteins may arrive at the apical sur-
face along a direct pathway. To define the polarized transport
properties of multimembrane-spanning PLP, HepG2 cells were
transfected with PLP-eGFP. In stably transfected cells, PLP-eGFP
was present prominently at the apical surface (Fig. 3B, arrow)
whereas a fraction was also detectable at the basolateral surface
(Fig. 3B, arrowhead). Surprisingly, the PLP-eGFP at the basolat-
eral membrane was not recognized by O10 (data not shown), im-
plying inaccessibility of PLP’s conformational O10 epitope in
HepG2 cells. However, antibody ET3 does recognize extracellular
PLP-eGFP at the basolateral surface (Fig. 3C). Unfortunately,
given the relative inaccessibility of the apical surface in HepG2
cells for exogenous labeling (Fig. 3A andC) (42), determination of
antibody ET3 recognition at this surface is essentially precluded.
Under steady-state conditions, PLP-eGFP associated primarily
with CHAPS-insoluble membrane microdomains (Fig. 3D, frac-
tions 3 and 4, approximately 56%) whereas only a minor fraction
was TX-100 insoluble (Fig. 3D, fractions 3 and 4, approximately
21%). Hence, under these conditions, PLP-eGFP partitioned in
microdomains, displaying detergent resistance properties similar
to those seen in primary OLGs (cf. Fig. 2B, mock). In situ extrac-
tion revealed that CHAPS-resistant PLP is present at both the
apical and basolateral membrane domains, whereas the PLP frac-
tion that resisted TX-100 extraction was associated exclusively
with the apical domain (Fig. 3E). Quantitative analysis based on
the use of MRP2 as a detergent-resistant apical marker revealed
that upon in situ extraction with TX-100, only 5 to 10% of the
MRP2-positive apical membranes are positive for PLP-eGFP,
whereas upon in situ extraction with CHAPS, 60 to 70% of the
apicalmembranes are positive for PLP (Fig. 3F). In untreated cells,
approximately 85% of the MRP2-positive apical membranes are
positive for PLP-eGFP. Since PLP localized at both surfaces, it was
of obvious interest to better define its transport itinerary. To verify
whether PLP-eGFP is transported in a direct manner to the apical
surface or, alternatively, may employ an indirect transcytotic
pathway from the basolateral to the apical surface, an antibody-
trafficking assay was performed (42). HepG2-PLP-eGFP cells
were incubated for 30min (on ice)with ET3 and then incubated at
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37°C for 90 min to activate trafficking. Subsequent immunocyto-
chemical analysis of the localization of the antibody-antigen com-
plex revealed that the antibody-stained PLP-eGFP became inter-
nalized but did not reach the apical membrane (Fig. 3G). In
contrast, DPPIV, a single-pass resident apical membrane protein
and a marker for basolateral-to-apical transcytosis in HepG2 cells
(42), was transported to the apical domain upon antibody inter-
nalization over the same incubation period (Fig. 3G), indicating
that basolateral-to-apical transcytosis is functional in HepG2 cells
that express PLP-eGFP. These findings suggest that PLP is directly
and effectively transported to the apical membrane in polarized
HepG2 cells following biosynthesis. Subsequently, PLP may en-
gage in transcytotic transport to the basolateral surface, where
reinternalization may occur without ensuing effective redelivery
of PLP to the apical surface.
To obtain further insight into the underlying mechanism that
drives polarized PLP transport, we focused on the potential role of
the galactolipids GalC and sulfatide. These galactolipids are highly
enriched in myelin; their expression precedes the appearance of
PLP in OLGs (2). Since GalC and sulfatide are not enriched in
HepG2 cells, we analyzed the expression of GalC and sulfatide in
PLP-eGFP-expressing HepG2 cells. Upon stable expression of
PLP-eGFP, the expression of sulfatide was dramatically greater
than that in parental cells (Fig. 3H, approximately 2-fold), sug-
gesting thatHepG2 cells likely adapt to PLP expression by increas-
ing the levels of sulfatide. This finding is rather surprising, given a
reported role for GalC-enriched microdomains but not sulfatide
in PLP transport to the myelin sheet (11). However, although it is
controversial, sulfatide has been implicated in PLP transport (48,
49). The apparently contradictory findings likely originate from
FIG 3 PLP-eGFP is present in the apical and basolateralmembrane domains of polarizedHepG2 cells. (A) Schematicmodel of polarizedHepG2 cells. The apical
(BC, red) and basolateral (blue) membrane domains are separated by tight junctions (green). (B) Localization of PLP-eGFP upon stable expression in HepG2
cells. Note that PLP-eGFP is present in the apical (arrow) and basolateral (arrowhead)membrane domains. (C) Localization of extracellular PLP (ET3) and total
PLP-eGFP (inset) at the basolateral surface of HepG2 cells. Nuclei were visualized with DAPI. (D) TX-100 and CHAPS membrane microdomain association of
PLP-eGFP in HepG2 cells. PLP-eGFP was visualized by Western blotting (anti-GFP antibody). Detergent-resistant membrane microdomains are present in
fractions 3 and 4. (E, F) HepG2-PLP-eGFP cells were left untreated (ctrl) or subjected to in situ detergent extraction with either TX-100 or CHAPS prior to
fixation. Apical membranes were visualized by immunostaining forMRP2 (E, insets, red). Note that TX-100-resistant PLP-eGFP localized to apical membranes,
whereas CHAPS-resistant PLP-eGFP resided at bothmembrane domains. The number of PLP-positive BCs among the totalMRP2-positive BCs was determined
under the conditions indicated (F). Each bar represents the mean result 	 the SD of four independent experiments. (G) Basolateral-to-apical transcytosis of
PLP-eGFP and DPPIV as analyzed by an antibody (Ab) trafficking assay. Antibodies (red) were visualized by immunostaining, and nuclei were stained with
DAPI. Note that DPPIV, but not PLP-eGFP (ET3), was transcytosed to the apical membrane domain. The localization of total PLP-eGFP is shown in the insets
(green) (H) TLC analysis of cellular glycosphingolipids in HepG2 and HepG2-PLP-eGFP cells. Pictures and blots representative of at least three independent
experiments are shown. Scale bars are 10 m.
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the different experimental conditions, including, among others,
the polarized status of the cells. Therefore, we next revisited the
role of sulfatide in PLP transport in OLGs.
Sulfatide is not essential for the transport of PLP to the cell
body plasma membrane. Previously, we have shown that GalC
and sulfatide are differently distributed in mOLGs, with GalC
preferentially localizing to myelin sheets and compact myelin
whereas sulfatide is largely excluded from myelin sheets and en-
riched in paranodes (50). To assess whether sulfatide is a priori
involved inmediating the transport of PLP, we next examined the
cellular localization of PLP in primary imOLGs, i.e., conditions
under which PLP transport to the cell body plasma membrane is
already apparent (cf. Fig. 1A), upon inhibition of sulfatide biosyn-
thesis with sodium chlorate fromOPCs onward. Sodium chlorate
is a competitive inhibitor of sulfation that inhibits sulfatide bio-
synthesis but not GalC biosynthesis (51–53). Furthermore, this
compound does not affect OLG viability and differentiation when
the cells are cultured on a PLL substrate (53). Labeling of cell
surface PLP (ET3), followed by fixation, permeabilization, and
staining of PLP with 4C2, revealed that in cells in which sulfatide
biosynthesis was blocked, PLP localized predominantly at the
plasmamembrane of the cell body, whereas in untreated cells, PLP
was localized mainly intracellularly (Fig. 4A, left panel). A quan-
titative analysis of the cells showing cell surface staining revealed a
3-fold increase in PLP surface staining upon inhibition of sulfatide
biosynthesis, compared to that in untreated cells (Fig. 4B). In con-
junction with the reduced intracellular staining of PLP (Fig. 4A),
the accumulated surface fraction of PLP presumably reflects a
decrease in PLP internalization by the cells. Remarkably, irrespec-
tive of sulfatide inhibition, PLP expressed on the surface of
imOLGs does not yet expose the O10 epitope (Fig. 4A and B).
Nevertheless, sulfatide is not essential for PLP transport to the
membrane surface of the cell body, given the presence of PLP at
the surface upon sulfatide depletion (Fig. 4A and B). To examine
the lateral membrane distribution of PLP at the cell surface in the
absence of sulfatide, untreated and sodium chlorate-treated
mOLGs were surface biotinylated; this was followed by detergent
extraction, density gradient centrifugation, and SA precipitation.
The fraction of PLP present at the surface of untreated OLGs was
partly TX-100 resistant andCHAPS resistant, whereas surface PLP
was still partly TX-100 resistant but CHAPS soluble in sodium
chlorate-treated, i.e., sulfatide-depleted, cells (Fig. 4C). Thus, sul-
fatide depletion results in the elimination of PLP’s localization in
CHAPS-resistantmicrodomains at the cell surface, indicating that
in cultured OLGs, the presence of sulfatide mediates a microdo-
main reallocation of cell surface-localized PLP, as reflected by a
detergent (in)solubility transition of PLP fromTX-100 to CHAPS
resistance. To further assess the role of sulfatide in PLP transport
and its lateral membrane distribution, we next made use of the
FIG 4 Sulfatide is not essential for the transport of PLP to the cell body plasmamembrane.OPCswere differentiated for 3 (A, B) or 7 (C) days in the absence (ctrl)
or presence of sodium chlorate, an inhibitor of sulfatide synthesis. (A) The surface localization of PLP was determined by immunostaining with anti-PLP
antibodies directed against extracellular epitopes (ET3, O10); this was followed by fixation, permeabilization, and staining with the 4C2 anti-PLP antibody. The
percentage of PLP surface-positive cells is shown in panel B. Statistically significant differences from the results obtained with untreated cells (ctrl) were assessed
with the Student t test (n 4; **, P 0.001). Note the prominent PLP surface expression (ET3 antibody) at the cell body plasma membrane upon inhibition of
sulfatide biosynthesis. (C) TX-100 and CHAPS membrane microdomain association of surface PLP. Cell surface proteins were biotinylated and subjected to
TX1-100 or CHAPS extraction, density gradient fractionation, and immunoprecipitation with SA-agarose. PLP was visualized by Western blotting (4C2
antibody). Note that surface PLP is TX-100 and CHAPS resistant in untreated cells but CHAPS soluble upon inhibition of sulfatide synthesis (chlorate). Pictures
and blots representative of at least three independent experiments are shown. Scale bars are 10 m.
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oligodendroglia-derived cell line OLN-93, which is deficient in
both PLP (30) and galactosphingolipids (Fig. 5A, mock).
Sulfatide is necessary for PLP’s reallocation to TX-100-solu-
ble membrane microdomains. SinceOLN-93 cells do not endog-
enously express PLP (30), we first stably expressed PLP-eGFP in
OLN-93 cells (OLN-PLP). Notably, the introduction of PLP-
eGFP did not affect the viability ofOLN-93 cells (data not shown),
while the expression level did not exceed the PLP expression levels
in primary OLGs (Fig. 5B, mock versus OLG). PLP-eGFP was
expressed prominently at the surface of galactolipid-deficient
OLN-PLP cells (Fig. 5D, mock), confirming that GalC and sul-
fatide are not required for transport to the plasma membrane.
Surface biotinylation experiments confirmed the plasma mem-
brane localization of PLP-eGFP in OLN-PLP cells (Fig. 5C, mock,
surface [S] versus intracellular [I]). Notably, a fraction of the PLP-
eGFP remained in the endoplasmic reticulum. Importantly, as in
primaryOLGs, overexpression of syntaxin 3 dramatically reduced
the levels of PLP on the OLN-PLP cell surface (Fig. 5D, S31,
arrow), suggesting a similarity in the underlying mechanisms of
plasma membrane-directed transport in both cell types. There-
fore, these findings are consistent with the previous finding that
sulfatide is not essential for the transport of PLP to the OLG
plasma membrane (Fig. 4) (51, 52). To further clarify the role of
GalC and sulfatide in the lateral membrane distribution of PLP,
OLN-PLP cells were transducedwith constructs that expressCGT,
the enzyme catalyzing the final step in GalC biosynthesis and/or
CST, which catalyzes the biosynthesis of sulfatide. TheGalC-over-
expressing and GalC- and sulfatide-overexpressing OLN-PLP
cells are referred to as OLN-PLP-G and OLN-PLP-GS, respec-
tively. TLC analysis revealed that, compared to mock-transduced
cells (OLN-PLP, i.e., vector only), OLN-PLP-G cells express sig-
nificant levels of GalC, while both GalC and sulfatide are present
in OLN-PLP-GS cells (Fig. 5A). Of interest, the presence of both
galactolipids and, to a lesser extent, the presence of GalC alone
resulted in an increase in total PLP expression (Fig. 5B) and an
approximately 2-fold increase in the surface expression of PLP-
eGFP (Fig. 5C). Given that PLP partitions in either TX-100- or
CHAPS-resistant membrane domains, the lateral distribution of
PLP-eGFP in OLN-PLP, OLN-PLP-G, and OLN-PLP-GS cells
was analyzed. InOLN-PLP-GS cells, PLP-eGFPwas CHAPS resis-
tant (Fig. 5E, fractions 3 and 4, approximately 77%) and TX-100
soluble (Fig. 5E, fractions 6 and 7, approximately 52%), in line
with PLP’s resistance in primary OLGs (Fig. 2B, mock) and
HepG2 cells (Fig. 3D). Strikingly, in galactolipid-deficient OLN-
PLP-mock cells, PLP-eGFP is TX-100 resistant (Fig. 5E, fractions
3 and 4, approximately 86%) and partly CHAPS resistant (Fig. 5E,
fractions 3 and 4, approximately 42%), while in sulfatide-deficient
OLN-PLP-G cells, PLP-eGFP is CHAPS resistant (Fig. 5E, frac-
tions 3 and 4, approximately 70%) and only partly TX-100 soluble
(Fig. 5E, fractions 6 and 7, approximately 32%). The observed
redistribution, reflected by the changes in detergent solubility,
appeared to be specific for PLP, since the localization of caveolin
FIG 5 Sulfatide is essential for segregation to TX-100-soluble membrane microdomains. (A) TLC analysis of cellular glycosphingolipids in OLN-PLP (mock),
OLN-PLP-G (GalC), and OLN-PLP-GS (GalC and sulfatide) cells. (B) Western blot analysis of PLP-eGFP expression in OLN-PLP cells (mock), OLN-PLP-G
cells, OLN-PLP-GS cells, OPCs, and OLGs (10 days of differentiation). PLP was visualized with anti-PLP antibody 2D2. (C) Cell surface proteins were
biotinylated, lysed, and immunoprecipitated with SA-agarose to separate surface-localized proteins (lanes S) and nonbiotinylated, i.e., intracellularly localized
proteins (lanes I). PLP-eGFPwas visualized byWestern blotting (anti-GFP antibody).Note that PLP-eGFP is present at the surface ofOLN-PLP cells (mock), i.e.,
in the absence of GalC (G) and sulfatide (S). (D) The surface localization of PLP-eGFP (ET3) was determined in mock-transduced (vector only) and syntaxin
3-overexpressing cells (S31). Note the decreased PLP-eGFP surface expression upon the overexpression of syntaxin 3 (arrow). (E) TX-100 and CHAPS
membranemicrodomain association of PLP-eGFP inOLN-PLP, OLN-PLP-G, andOLN-PLP-GS cells. PLP-eGFPwas visualized byWestern blotting (anti-GFP
antibody). Detergent-resistantmembranemicrodomains are present in fractions 3 and 4.Note that PLP-eGFP is TX-100 resistant in the absence of sulfatide. PLP
(4C2) and caveolin were visualized by Western blotting. Pictures and blots representative of at least three independent experiments are shown. The scale bar is
10 m.
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in membrane microdomains remained unaltered, irrespective of
the presence of galactolipids. In all of the OLN lines, PLP acquired
CHAPS resistance, indicating that in these cells, the presence of
sulfatide is not a prerequisite for PLP’s sequestration in CHAPS-
resistant domains. Hence, the presence of sulfatide caused PLP-
eGFP to redistribute into membrane microdomains that are
soluble in TX-100. Since PLP transiently associates with TX-100-
resistant membrane domains, i.e., upon its biosynthesis, while the
protein acquires CHAPS resistance in subsequent transcytotic
transport, we next determined the location and underlying driv-
ing force of this shift in lateral membrane distribution.
Sulfatide-dependent redistribution of PLP to different mi-
crodomains at the plasma membrane. To determine whether
PLP, after arrival at the plasmamembrane, and sulfatidemay par-
tition within the same membrane domains at the cell surface, we
first determined the potential colocalization of PLP with either
anti-GalC (O1) or antisulfatide (O4) antibodies in live OLN-
PLP-GS cells. PLP-eGFP colocalizedwith sulfatide but notGalC at
the cell surface (Fig. 6A, inset). Of note, surface labeling with anti-
PLP antibody O10 showed colocalization with PLP-eGFP (data
not shown). In fixed and permeabilized OLN-PLP-GS cells (Fig.
6A), intracellular PLP-eGFP colocalized with GalC but not sul-
fatide (Fig. 6A). The intracellular sulfatide patches colocalized
with LAMP1 but not EEA1 (data not shown, Fig. 6B), and this
might be a reflection of a reduced ability to degrade sulfatide in
OLN-PLP-GS cells. As shown, in the presence of sulfatide, an in-
creasing PLP fraction redistributed fromTX-100-insoluble to TX-
100-soluble membrane domains (Fig. 5E and 4C). To determine
the cellular location of PLP’s redistribution to TX-100-soluble
membrane microdomains, i.e., at the plasma membrane or upon
internalization, subcellular fractions enriched in endosomes and
lysosomes were isolated and separated on a discontinuous sucrose
gradient (38, 39) (Fig. 6B); this was followed by either TX-100 or
CHAPS extraction. In OLN-PLP-GS cells, PLP-eGFP is TX-100
soluble but CHAPS resistant in both endosomes and lysosomes
(Fig. 6C), indicating that the detergent (in)solubility shift, as in
HepG2 cells (Fig. 3, data not shown), likely occurred at the cell
surface or immediately following internalization. In OLN-PLP
cells, i.e., cells that do not express galactolipids, PLP-eGFP is
CHAPS soluble in the enriched endosomal fraction but CHAPS
resistant in the enriched lysosomal fraction (Fig. 6C). Of note, in
OLN-PLP cells, a larger fraction of PLP-eGFP is present in the
enriched endosomal fraction than in the enriched lysosomal frac-
tion, compared to its distribution in OLN-PLP-GS cells (Fig. 6B).
Hence, the detergent analysis suggests that sulfatide potentially
induces a lateral redistribution of PLP in the plasmamembrane of
OLGs, which was examined next in live cells.
Sulfatide modulates the conformation of PLP. Presumably, a
change in the lateral microenvironment of a membrane protein
may be related to changes in the protein’s structure, including its
oligomerization. By employing the three available anti-extracellu-
lar PLP antibodies in the OLN-PLP cell lines, we investigated the
possibility that PLP could undergo such changes when sensing the
presence of sulfatide at the level of the plasma membrane. Immu-
FIG 6 PLP is conveyed from TX-100- to CHAPS-resistant membrane microdomains at the plasma membrane. (A) Colocalization of PLP-eGFP with GalC
and/or sulfatide in OLN-PLP-GS cells. Immunostaining with anti-GalC (O1) and antisulfatide (O4) antibodies was performed with live or fixed and permeab-
ilized cells. Note that PLP-eGFP colocalized with sulfatide but not GalC at the surface of OLN-PLP-GS cells, whereas intracellular PLP-eGFP partially colocalized
with GalC but not sulfatide (insets). (B, C) Endosomes and lysosomes were separated by organelle fractionation and centrifugation on a discontinuous sucrose
gradient. The distribution of EEA1, LAMP1, and PLP-eGFP (anti-GFP antibody) was visualized byWestern blotting. The distribution of sulfatide was visualized
with a dot blotting assay using antisulfatide antibody O4 for detection. The boxes mark the pooled fractions of the gradient used for TX-100 and CHAPS
extraction of the enriched endosomal and lysosomal fractions shown in panel C. Detergent-resistant membrane microdomains are present in fractions 3 and 4.
Note that PLP-eGFP is TX-100 soluble and CHAPS insoluble in both endosomes and lysosomes in OLN-PLP-GS cells but still CHAPS soluble in endosomes in
galactolipid-deficient OLN-PLP cells. The scale bar is 10 m.
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nocytochemical analysis of live cells revealed that antibody 4C2,
which is directed against a nonconformational epitope in the first
extracellular loop (35), recognizes PLP-eGFP at the surface of vir-
tually all OLN-PLP, OLN-PLP-G, and OLN-PLP-GS cells (Fig.
7A), confirming the biochemical analysis (cf. Fig. 5C) that PLP
reaches the surface independently of the presence of sulfatide.
Similarly, when applying antibody ET3, which recognizes a con-
formational epitope in the second extracellular loop, prominent
surface staining was observed on all three OLN-PLP lines (Fig.
7A). Remarkably, in linewith the observation in primaryOLGs, in
OLN-PLP-GS cells, the ET3 epitope is exposed mainly at the cell
body, while in OLN-PLP and OLN-PLP-G cells, ET3 binds in
addition to PLP present at the processes. In contrast, the O10
epitope emerged in OLN-PLP-GS cells (Fig. 7A and B) but was
hardly detectable in OLN-PLP and OLN-PLP-G cells, suggesting
that the presence of sulfatide is sensed by PLP, which apparently
adjusted its structure in terms of conformation. Importantly, the
O10 epitope emerges only when PLP reaches a functional tertiary
structure and/or oligomerizes (36), while the secondary structure
of the second extracellular loop changes as a function of its envi-
ronment (37). Given that, in OLGs and OLN-PLP-GS cells, ET3
recognizes PLP mainly at the cell body plasma membrane, where
sulfatide is enriched (50), whereas the O10 epitope is more prom-
inently exposed at the myelin sheet (Fig. 1B and C), it is tempting
to suggest that sulfatide likely initiates structural changes in PLP
upon its internalization. In addition, given that O10 does recog-
nize PLP-eGFP at the surface of OLN-PLP-GS cells but not that of
HepG2 cells (see above), this finding indicates that a component
that is necessary for exposure of the O10 epitope is apparently
lacking in the basolateral membrane of HepG2 cells.
DISCUSSION
In the present work, we have shown that myelin biogenesis in
OLGs at least partly relies on the involvement of a transcytotic
transportmechanism, as reflected bymyelin-directed transport of
PLP. Thus, our data support a model in which PLP, early after
biosynthesis, integrates into distinct membrane domains charac-
terized by TX-100 insolubility for transport to the plasma mem-
brane of the OLG cell body, which relies on syntaxin 3-mediated
docking (Fig. 8). At the plasmamembrane, at least part of the PLP
fraction is redistributed into membrane domains that are charac-
terized by TX-100 solubility but CHAPS resistance, consistent
with previously reported observations (11). Interestingly, inhibi-
tion of sulfatide biosynthesis in primary OLGs and parallel exper-
iments with OLN-93 cells expressing GalC or GalC and sulfatide
indicate that sulfatide is instrumental in this shift in membrane
domain localization, likely related to a sulfatide-induced confor-
mational change in and/or oligomerization of the protein. Given
FIG 7 Sulfatide modulates the conformation of PLP at the plasma membrane. Surface expression of PLP-eGFP in differentiated OLN-PLP, OLN-PLP-G, and
OLN-PLP-GS cells with three different anti-PLP antibodies against extracellular epitopes, i.e., the first (4C2) and second (O10, ET3) extracellular loops.Note that
O10 recognizes surface PLP-eGFP onlywhen sulfatide is present (A).Quantification of the number ofO10-positive cells among the total number of cells is shown
in panel B. Each bar represents the mean value plus the SD. Statistically significant differences from the results obtained with OLN-PLP cells were assessed by
one-way ANOVA with Tukey’s posttest (n 3; ***, P 0.001). The scale bar is 10 m.
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that PLP is transported to the plasmamembrane in the absence of
sulfatide, while it remains TX-100 resistant for 30 to 60 min fol-
lowing its biosynthesis, PLP likely encounters sulfatide after
reaching the cell body plasmamembrane. As shown previously, as
part of the apical-to-basolateral transport process, PLP becomes
integrated into cholesterol- and GalC-enriched microdomains in
myelin membranes, suggesting its eventual dissociation from sul-
fatide (11). Evidently, a transcytotic mechanismwould be entirely
in linewith our previous contentions thatOLGs can be envisioned
as polarized cells, displaying properties similar to those reported
for typical polarized cells like epithelial cells. In fact, in the present
work, we demonstrate that in such cells, i.e., hepatocytes, the ma-
jor epithelial cells in the liver, PLP transcytotic transport may oc-
cur between the apical and basolateral surfaces.
Our observations indicate that transport of PLP to the myelin
membrane relies on a syntaxin 3- but not syntaxin 4-dependent
mechanism. Thus, following biosynthesis, PLP is transported to
the apical-surface-like plasma membrane of the cell body in a
syntaxin 3-dependent manner, after which the protein is laterally
reallocated, internalized, and directed toward the myelin sheet. A
transient localization of PLP at the cell body plasma membrane,
followed by its subsequent internalization via endocytosis, would,
as a matter of mechanistic principle, also be consistent with ob-
servations reported by others (17, 23). Although syntaxin 3 is
clearly involved in the delivery of PLP at the cell body plasma
membrane following biosynthesis, the t-SNARE involved in dock-
ing of PLP at the myelin membrane remains to be determined. A
possible candidate is syntaxin 2, which localizes to myelin sheets
(our unpublished observations; 27).
At first glance, our data are inconsistent with the studies of
Feldmann et al. (24). They proposed that vesicular delivery of PLP
from endosomal compartments to themyelinmembrane relies on
VAMP7, the cognate v-SNARE partner of syntaxin 3, whereas our
findings indicate an earlier role for syntaxin 3, i.e., in the biosyn-
thetic pathway to the plasma membrane, rather than the transcy-
totic pathway.However, the conclusion of Feldmann et al. (24) on
the localization of VAMP7 was based primarily on studies with
GFP-VAMP7 constructs in mouse-derived Oli-neu cells that ex-
press sulfatide (54), whereas our data are derived frommature rat
OLGs. On the basis of the present findings, it would be of interest
to determine the nature of the detergent sensitivity of the PLP-
containing transport vesicles and sulfatide dependence upon
VAMP7 dysfunctioning, either by downregulation or overexpres-
sion of the v-SNARE, analogously as reported in the present study
for a syntaxin 3 dependence of PLP transport. Nevertheless, my-
elin defects arise when interfering with VAMP7-mediated but not
VAMP3-mediated vesicular transport, which emphasizes that the
cognate VAMP7-syntaxin 3 pair but not the VAMP3-syntaxin 4
pair, is essential for PLP transport to myelin membranes (24),
which is entirely consistent with our observation in primary
OLGs.
A hallmark of the transcytotic transport route of PLP is its
transient partitioning into distinct membrane domains at differ-
ent stages of its processing after de novo biosynthesis. Thus, fol-
lowing its biosynthesis, PLP is transported from the trans-Golgi
network in a TX-100-insoluble membrane microdomain fraction
to the cell body plasma membrane, where the protein is redistrib-
uted to TX-100-solublemembrane domains that, in time, become
resistant to CHAPS solubilization. A similar sequential shift be-
tween distinct membrane domains, reflected by differences in de-
tergent (in)solubility, was observed in polarized HepG2 cells. In
further support of such a sequence of events and its functional
consequences are observations reported by Simons et al. (11, 55)
that the kinetics of PLP’s acquirement of TX-100 solubility appear
to be commensurate with those of acquiring CHAPS insolubility.
More specifically, PLP is largely CHAPS soluble at the Golgi ap-
paratus, and only after 30 to 60min, i.e., likely the time required to
reach the plasmamembrane, PLP is redistributed from a TX-100-
insoluble to a CHAPS-insoluble domain (Fig. 2) (11). As noted
above, this detergent-sensitive shift likely takes place at the apical-
surface-like cell body plasmamembrane rather than within endo-
cytic compartments. Presumably, this lateral sorting stepmight be
involved in the subsequent internalization and transport of PLP
from the plasma membrane to endosomal compartments, which
are instrumental in transcytosis (56) and subsequent delivery to
the myelin membrane.
Our data indicate that sulfatide is presumably responsible for
the lateral reallocation to distinct membrane microdomains.
Thus, in primary OLGs, sulfatide, rather than GalC, conveys TX-
100 solubility to PLP, prior to its integration into CHAPS-resis-
tant domains, a finding that is consistent with observations in
mice that are unable to synthesize GalC and sulfatide. In these
mice, amajor fraction of PLP resides in TX-100-resistant domains
and fails to segregate into CHAPS-resistant domains (11). The
underlying mechanism by which sulfatide sequesters PLP from
TX-100-insoluble domains remains to be determined, although a
sulfatide-induced conformational alteration and/or oligomeriza-
tion of PLP, as stated in the present report, may be of relevance in
this regard.However, of interest in this context is also the reported
FIG 8 Schematic overview of the trafficking of de novo-synthesized PLP to
myelin sheets via transcytosis. (Part 1) Transport of PLP from the trans-Golgi
network to the apical-surface-like (red) cell body plasma membrane is syn-
taxin 3 dependent and sulfatide independent and occurs as part of a TX-100-
insoluble, CHAPS-soluble membrane microdomain (part 2). At the plasma
membrane, PLP is redistributed to TX-100-soluble, CHAPS-insoluble mi-
crodomains, a process that is sulfatide mediated and likely involves a confor-
mational alteration and/or oligomerization (part 3). Transport from the
plasma membrane of the cell body to the basolateral-surface-like (blue) my-
elin-like membranes occurs by means of TX-100-soluble, CHAPS-insoluble
microdomains. Along this route, PLP likely accumulates temporally in a late
endosomal compartment (11, 12). See the text for further details.
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cholesterol dependence of PLP’s internalization before the ac-
quirement of CHAPS insolubility and exposure of the O10
epitope (11, 22). Given that PLP and sulfatide may both associate
with cholesterol (45, 57), such interactions can affect the physico-
chemical properties of microdomains and hence their content
(58). As a consequence, sulfatide- and cholesterol-dependent in-
vagination may be triggered, allowing subsequent transcytotic
transport to the myelin sheet. Moreover, a preferential role for
sulfatide in endocytosis in OLGs has been reported (59).
Taking the results together, we show here that, along with be-
ing a key compound of the regulation of the timing of terminal
OLG differentiation (53, 60, 61), sulfatide is also a key regulator of
transcytotic PLP transport, presumably relying in part on a sul-
fatide-induced conformational change. This may allow for the
regulated timing of PLP’s appearance in myelin membranes,
thereby preventing premature and ectopic compaction. Remark-
ably, in vivo, PLP transport tomyelinmembranes is uninterrupted
in the absence of sulfatide (51, 52, 62). It is likely, under these
conditions, that PLP trafficking is not temporally regulated and is
transported tomyelinmembranes by bulk flow or by an unknown
compensatory, likely nontranscytotic, mechanism that allows
CHAPS-soluble and possibly TX-100-insoluble PLP to insert into
myelin membranes. Of interest in this context is that in the ab-
sence of sulfatide, a nonselective association with myelin-directed
vesicles has been noted (63). In addition, sulfatide interacts with
several key adhesion and ECM proteins, including laminin-2 (64,
65), which is secreted by developing axons (66) and promotes
myelin biogenesis (reviewed in reference 67).Hence, it is tempting
to suggest that the recently reported interaction between
laminin-2 and sulfatide in OLGs (53) might regulate (transcy-
totic) PLP transport in vivo, a process thatmay be disrupted inMS.
These issues are currently being investigated in our laboratory.
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